ArticleClinical lymphoma, myeloma & leukemia2020

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.

Sudhir Manda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.